Pathophysiology and Clinical Features of TTR Cardiac Amyloidosis: No Longer a “Rare” Disease and Still Underdiagnosed Closing Knowledge Gaps in Transthyretin Cardiomyopathy (ATTR-CM)

Health Care Practitioners (HCPs) have a pivotal role in ensuring the right patients get the right treatment. Patients living with ATTR-CM have new treatment options that have recently become available.  In order to accurately diagnose and treat symptoms unique to the ATTR-CM patient, HCPs need to be aware of the application of guideline-based systematic, multimodal imaging and clinical diagnostics related to ATTR-CM. This podcast will highlight the latest terminology, treatments and guidelines for this no longer rare disease.